Featured Publications
Illusory generalizability of clinical prediction models
Chekroud A, Hawrilenko M, Loho H, Bondar J, Gueorguieva R, Hasan A, Kambeitz J, Corlett P, Koutsouleris N, Krumholz H, Krystal J, Paulus M. Illusory generalizability of clinical prediction models. Science 2024, 383: 164-167. PMID: 38207039, DOI: 10.1126/science.adg8538.Peer-Reviewed Original Research
2023
Randomized controlled trial of the glycine transporter 1 inhibitor PF-03463275 to enhance cognitive training and neuroplasticity in schizophrenia
Surti T, Ranganathan M, Johannesen J, Gueorguieva R, Deaso E, Kenney J, Krystal J, D'Souza D. Randomized controlled trial of the glycine transporter 1 inhibitor PF-03463275 to enhance cognitive training and neuroplasticity in schizophrenia. Schizophrenia Research 2023, 256: 36-43. PMID: 37141764, PMCID: PMC10257994, DOI: 10.1016/j.schres.2023.04.010.Peer-Reviewed Original ResearchMeSH KeywordsAntipsychotic AgentsCognitive TrainingDouble-Blind MethodGlycine Plasma Membrane Transport ProteinsHumansNeuronal PlasticitySchizophreniaConceptsGlycine transporter 1Cytochrome P450 2D6 extensive metabolizersGlyT1 inhibitorsWeeks of washoutWeeks of CTMedication adherenceReceptor hypofunctionImpaired neuroplasticityPharmacodynamic variabilityNMDAR functionExtensive metabolizersTreatment periodPsychotic symptomsStable outpatientsCognitive impairmentGlyT1 occupancyTransporter 1CTNeuroplasticityCognitive training strategiesSchizophreniaComputerized CTCognitive performanceAugmentation studiesGreater improvement
2012
Efficacy of pimozide augmentation for clozapine partial responders with schizophrenia
Gunduz-Bruce H, Oliver S, Gueorguieva R, Forselius-Bielen K, D'Souza DC, Zimolo Z, Tek C, Kaliora S, Ray S, Petrides G. Efficacy of pimozide augmentation for clozapine partial responders with schizophrenia. Schizophrenia Research 2012, 143: 344-347. PMID: 23219861, DOI: 10.1016/j.schres.2012.11.008.Peer-Reviewed Original ResearchConceptsBrief Psychiatric Rating ScaleTreatment-resistant schizophreniaClinical trialsNegative symptomsDouble-blind placeboAdequate blood levelsPsychiatric Rating ScaleNeurocognitive measuresAttention/executive functionBPRS totalPartial respondersPartial responseStudy entryQTc intervalBlood levelsClozapine's effectSide effectsNeurocognitive functionPatientsWeekly assessmentsClozapineNeurocognitive testsRating ScaleSchizophreniaTrials
2010
Incidence of tardive dyskinesia with atypical versus conventional antipsychotic medications: a prospective cohort study.
Woods SW, Morgenstern H, Saksa JR, Walsh BC, Sullivan MC, Money R, Hawkins KA, Gueorguieva RV, Glazer WM. Incidence of tardive dyskinesia with atypical versus conventional antipsychotic medications: a prospective cohort study. The Journal Of Clinical Psychiatry 2010, 71: 463-74. PMID: 20156410, PMCID: PMC3109728, DOI: 10.4088/jcp.07m03890yel.Peer-Reviewed Original ResearchMeSH KeywordsAdolescentAdultAgedAmbulatory CareAntipsychotic AgentsCohort StudiesCommunity Mental Health CentersConnecticutDiagnostic and Statistical Manual of Mental DisordersDyskinesia, Drug-InducedFemaleHumansIncidenceLongitudinal StudiesMaleMental DisordersMiddle AgedPrevalenceProspective StudiesPsychiatric Status Rating ScalesRisk FactorsSeverity of Illness IndexConceptsProspective cohort studyConventional antipsychoticsTardive dyskinesiaAtypical antipsychoticsCohort studyPrevious prospective cohort studyCommunity mental health centerConventional antipsychotic medicationsMental health centersAntipsychotic medicationHealth centersBaseline evaluationAntipsychoticsNew diagnosisDyskinesiaClinical practicePsychiatric outpatientsRecent exposureIncidencePrevious visitPrevious studiesPrevalenceSubjectsCurrent studyMost previous studies
2005
Control Group Bias in Randomized Atypical Antipsychotic Medication Trials for Schizophrenia
Woods SW, Gueorguieva RV, Baker CB, Makuch RW. Control Group Bias in Randomized Atypical Antipsychotic Medication Trials for Schizophrenia. JAMA Psychiatry 2005, 62: 961-970. PMID: 16143728, DOI: 10.1001/archpsyc.62.9.961.Peer-Reviewed Original ResearchMeSH KeywordsAge FactorsAntipsychotic AgentsBrief Psychiatric Rating ScaleDouble-Blind MethodDrug Administration ScheduleFemaleHumansMalePlacebosPsychotic DisordersRandomized Controlled Trials as TopicResearch DesignSchizophreniaSchizophrenic PsychologySelection BiasSeverity of Illness IndexSex FactorsTreatment OutcomeConceptsBrief Psychiatric Rating ScalePlacebo-controlled trialPsychiatric Rating ScalePlacebo-controlled studyAtypical antipsychotic medicationsDose-controlled studyMedication trialsAntipsychotic medicationRating ScaleDouble-blind clinical trialNew atypical antipsychotic medicationsDose-controlled trialsTreatment completion ratesPlacebo control groupEnd point changePercentage of menDrug Administration databaseRandom effects analysisIll adultsMedication armClinical trialsNew medicationsNovel medicationsSame drugAverage age
2003
Transcranial Magnetic Stimulation of Left Temporoparietal Cortex and Medication-Resistant Auditory Hallucinations
Hoffman RE, Hawkins KA, Gueorguieva R, Boutros NN, Rachid F, Carroll K, Krystal JH. Transcranial Magnetic Stimulation of Left Temporoparietal Cortex and Medication-Resistant Auditory Hallucinations. JAMA Psychiatry 2003, 60: 49-56. PMID: 12511172, DOI: 10.1001/archpsyc.60.1.49.Peer-Reviewed Original ResearchConceptsRepetitive transcranial magnetic stimulationMedication-resistant auditory hallucinationsTranscranial magnetic stimulationLeft temporoparietal cortexAuditory hallucinationsSham stimulationMagnetic stimulationTemporoparietal cortexOpen-label trialMotor thresholdAntipsychotic medicationSustained reductionBrain areasSchizoaffective disorderCortical activationPossible treatmentNeuropsychological impairmentNeuropsychological assessmentPatientsAdditional studiesCortexStimulationTrialsHallucinationsTreatment effects